Investors and Partners

Q-Sera’s technology is based on intellectual property from The University of Queensland (UQ) Centre for Clinical Research, which was identified and developed by UniQuest, the main commercialization company of The University of Queensland.


Q-Sera has the support of leading Australian Investors, Uniseed and the Medical Research Commercialization Fund (MRCF).

About UniQuest

UniQuest is Australia’s leading university commercializing entity, managing the intellectual property of The University of Queensland. It benchmarks in the top 10 percent globally for university-based technology transfer offices.  UniQuest and its spin-out companies have raised more than A$630 million to help take UQ technologies to market and returned more than A$435 million in revenue to UQ. Since 2007, gross sales of products using UQ technology licensed by UniQuest total more than $16 billion.  Among others, UniQuest was responsible for commercializing the HPV vaccine Gardasil®, the Triple P Positive Parenting Program, the imaging technology used in two-thirds of the world’s MRI machines, and a potential new treatment for pain through spin-out company Spinifex Pharmaceuticals Pty Ltd – one of Australia’s largest ever biotech acquisitions. For more information, visit

About Uniseed

Uniseed is a $70 million venture fund operating at the Universities of Melbourne, Queensland, New South Wales and Sydney, as well as the CSIRO. Uniseed’s mandate is to facilitate the commercialization of research partner-generated intellectual property by targeting investment in highly promising technologies. Uniseed helps researchers from its partner research organizations to turn their ideas into products and services and to support innovations that solve market problems and create a positive impact for the community. Uniseed’s investments cover a range of technology sectors and to date, the fund has exited four investments through trade sales and one investment through asset sale. A number of companies in Uniseed’s investment portfolio also have products on the market, or are collaborating with leading global companies in their respective fields. For more information, visit


About The Medical Research Commercialization Fund (MRCF) and Brandon Capital

Brandon Capital Partners is a venture capital firm that manages The Medical Research Commercialization Fund (MRCF), Australia and New Zealand’s largest life science investment fund, with AU$505 million under management.
The MRCF is a unique collaboration between major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals. The MRCF supports the development and commercialization of early-stage biomedical discoveries originating from member research organizations, providing both capital and expertise to guide the successful development of new therapies. The MRCF has supported more than 34 start-up companies to date, 28 of which were founded by the MRCF. Brandon Capital’s funds have invested in some of the most promising life sciences companies, including: Aravax, Global Kinetics Corporation, PolyActiva, Q-Sera, Osprey Medical and Vaxxas.

For more information, visit

Supported by the Australian Government through Accelerating Commercialisation, an element of the Entrepreneur’s Programme.